Abstract
Novel psychoactive substances (NPSs) are new psychotropic drugs designed to evade substance regulatory policies. 25E-NBOMe (2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine) has recently been identified as an NPS, and its recreational misuse has been reported to be rapidly increasing. However, the psychopharmacological effects and mechanisms of 25E-NBOMe have not been studied. We examined the abuse potential of 25E-NBOMe using the conditioned place preference in male mice and self-administration paradigms in male rats. Additionally, immunoblot assay, enzyme-linked immunosorbent assay, and microdialysis were used to determine the molecular effects of 25E-NBOMe in the nucleus accumbens (NAc). Our data demonstrated that 25E-NBOMe induces conditioned place preference, and the dopaminergic signaling in the NAc mediates these. Following 25E-NBOMe administration, expression of dopamine transporter and dopamine D1 receptor (D1DR) were enhanced in the NAc of male mice, and NAc dopamine levels were reduced in both male mice and rats. Induction of intracellular dopaminergic pathways, DARPP32, and phosphorylation of CREB in the NAc of male mice was also observed. Significantly, pharmacological blockade of D1DR or chemogenetic inhibition of D1DR-expressing medium spiny neurons in the NAc attenuated 25E-NBOMe-induced conditioned place preference in male mice. We also examined the hallucinogenic properties of 25E-NBOMe using the head twitch response test in male mice and found that this behavior was mediated by serotonin 2A receptor activity. Our findings demonstrate that D1DR signaling may govern the addictive potential of 25E-NBOMe. Moreover, our study provides new insights into the potential mechanisms of substance use disorder and the improvement of controlled substance management.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bateup HS, Svenningsson P, Kuroiwa M, Gong S, Nishi A, Heintz N, Greengard P (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci 11(8):932–939. https://doi.org/10.1038/nn.2153
Beaulieu JM, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63(1):182–217. https://doi.org/10.1124/pr.110.002642
Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Hervé D, Valjent E, Girault JA (2008) Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28(22):5671–5685. https://doi.org/10.1523/JNEUROSCI.1039-08.2008
Bortolozzi A, Díaz-Mataix L, Scorza MC, Celada P, Artigas F (2005) The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95(6):1597–1607. https://doi.org/10.1111/j.1471-4159.2005.03485.x
Bubar MJ, Cunningham KA (2006) Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6(18):1971–1985. https://doi.org/10.2174/156802606778522131
Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V (2015) Tolerance to LSD and DOB induced shaking behaviour: differential adaptations of frontocortical 5-HT(2A) and glutamate receptor binding sites. Behav Brain Res 281:62–68. https://doi.org/10.1016/j.bbr.2014.12.014
Buchborn T, Lyons T, Knöpfel T (2018) Tolerance and tachyphylaxis to head twitches induced by the 5-HT2A agonist 25CN-NBOH in mice. Front Pharmacol 9:17. https://doi.org/10.3389/fphar.2018.00017
Calipari ES, Bagot RC, Purushothaman I, Davidson TJ, Yorgason JT, Peña CJ, Walker DM, Pirpinias ST, Guise KG, Ramakrishnan C, Deisseroth K, Nestler EJ (2016) In vivo imaging identifies temporal signature of D1 and D2 medium spiny neurons in cocaine reward. Proc Natl Acad Sci U S A 113(10):2726–2731. https://doi.org/10.1073/pnas.1521238113
Calipari ES, Juarez B, Morel C, Walker DM, Cahill ME, Ribeiro E, Roman-Ortiz C, Ramakrishnan C, Deisseroth K, Han MH, Nestler EJ (2017) Dopaminergic dynamics underlying sex-specific cocaine reward. Nat Commun 8:13877. https://doi.org/10.1038/ncomms13877
Canal CE, Morgan D (2012) Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. Drug Test Anal 4(7–8):556–576. https://doi.org/10.1002/dta.1333
Cervo L, Samanin R (1995) Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Res 673(2):242–250. https://doi.org/10.1016/0006-8993(94)01420-m
Chatwin C (2017) Assessing the ‘added value’ of European policy on new psychoactive substances. Int J Drug Policy 40:111–116. https://doi.org/10.1016/j.drugpo.2016.11.002
Corkery JM, Orsolini L, Papanti D, Schifano F (2017) From concept(ion) to life after death/the grave: The “natural” history and life cycle(s) of novel psychoactive substances (NPS). Hum Psychopharmacol. https://doi.org/10.1002/hup.2566
Custodio RJP, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, Lee HJ, Yoo SY, Lee KW, Lee YS, Seo JW, Ryu IS, Kim HJ, Cheong JH (2020) 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: evidence of abuse potential. Addict Biol 25(6):e12850. https://doi.org/10.1111/adb.12850
de la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, González-Maeso J (2022) Tolerance and cross-tolerance among psychedelic and nonpsychedelic 5-HT2A receptor agonists in mice. ACS Chem Neurosci 13(16):2436–2448. https://doi.org/10.1021/acschemneuro.2c00170
Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15(1 Pt 2):821–829. https://doi.org/10.1523/JNEUROSCI.15-01-00821.1995
Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, Acquas E, Carboni E, Valentini V, Lecca D (2004) Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47:227–241. https://doi.org/10.1016/j.neuropharm.2004.06.032
Drug Enforcement Administration (2016) Schedules of controlled substances: placement of three synthetic phenethylamines into schedule I. final rule. Fed Regist 81(187):66181–66184. Federal Register Web. https://www.govinfo.gov/content/pkg/FR-2016-09-27/pdf/2016-23185.pdf
Ellenbroek B, Youn J (2016) Rodent models in neuroscience research: is it a rat race? Dis Model Mech 9(10):1079–1087. https://doi.org/10.1242/dmm.026120
Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH (2018) Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2 C counterparts in male rats. Neuropharmacology 142:240–250. https://doi.org/10.1016/j.neuropharm.2018.02.033
Eshleman AJ, Wolfrum KM, Reed JF, Kim SO, Johnson RA, Janowsky A (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: high potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27–34. https://doi.org/10.1016/j.bcp.2018.09.024
Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH (2004) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology 173(3–4):270–277. https://doi.org/10.1007/s00213-003-1741-2
Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, Cheramy A, O’Callaghan JP, Miller DB, Cole DG, Corbett R, Haile CN, Cooper DC, Onn SP, Grace AA, Ouimet CC, White FJ, Hyman SE, Surmeier DJ, Girault J, Nestler EJ, Greengard P (1998) DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science 281(5378):838–842. https://doi.org/10.1126/science.281.5378.838
Foster JD, Vaughan RA (2017) Phosphorylation mechanisms in dopamine transporter regulation. J Chem Neuroanat 83–84:10–18. https://doi.org/10.1016/j.jchemneu.2016.10.004
Gong S, Fayette N, Heinsbroek JA, Ford CP (2021) Cocaine shifts dopamine D2 receptor sensitivity to gate conditioned behaviors. Neuron 109(21):3421–3435e5. https://doi.org/10.1016/j.neuron.2021.08.012
González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53(3):439–452. https://doi.org/10.1016/j.neuron.2007.01.008
Gould TD, Manji HK (2005) DARPP-32: a molecular switch at the nexus of reward pathway plasticity. Proc Natl Acad Sci U S A 102(2):253–254. https://doi.org/10.1073/pnas.0408700102
Green TA, Bardo MT (2020) Opposite regulation of conditioned place preference and intravenous drug self-administration in rodent models: motivational and non-motivational examples. Neurosci Biobehav Rev 116:89–98. https://doi.org/10.1016/j.neubiorev.2020.06.006
Gu SM, Cha HJ, Seo SW, Hong JT, Yun J (2020) Dopamine D1 receptor antagonist reduces stimulant-induced conditioned place preferences and dopamine receptor supersensitivity. Naunyn Schmiedebergs Arch Pharmacol 393(1):131–138. https://doi.org/10.1007/s00210-019-01694-3
Halberstadt AL (2017) Pharmacology and toxicology of N-benzylphenethylamine (NBOMe) hallucinogens. Curr Top Behav Neurosci 32:283–311. https://doi.org/10.1007/7854_2016_64
Halberstadt AL, Geyer MA (2011) Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 61(3):364–381. https://doi.org/10.1016/j.neuropharm.2011.01.017
Halberstadt AL, Geyer MA (2014) Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2 C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77:200–207. https://doi.org/10.1016/j.neuropharm.2013.08.025
Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (2014) Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2 C agonists. ACS Chem Neurosci 5(3):243–249. https://doi.org/10.1021/cn400216u
Herian M, Skawski M, Wojtas A, Sobocińska MK, Noworyta K, Gołembiowska K (2021) Tolerance to neurochemical and behavioral effects of the hallucinogen 25I-NBOMe. Psychopharmacology 238(8):2349–2364. https://doi.org/10.1007/s00213-021-05860-5
Homberg JR, Wöhr M, Alenina N (2017) Comeback of the rat in biomedical research. ACS Chem Neurosci 8(5):900–903. https://doi.org/10.1021/acschemneuro.6b00415
Howell LL, Cunningham KA (2015) Serotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. Pharmacol Rev 67(1):176–197. https://doi.org/10.1124/pr.114.009514
Jeon SY, Kim YH, Kim SJ, Suh SK, Cha HJ (2019) Abuse potential of 2-(4-iodo-2, 5-dimethoxyphenyl)N-(2-methoxybenzyl)ethanamine (25INBOMe); in vivo and ex vivo approaches. Neurochem Int 125:74–81. https://doi.org/10.1016/j.neuint.2019.02.007
Jo C, Joo H, Youn DH, Kim JM, Hong YK, Lim NY, Kim KS, Park SJ, Choi SO (2022) Rewarding and reinforcing effects of 25H-NBOMe in rodents. Brain Sci 12(11):1490. https://doi.org/10.3390/brainsci12111490
Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153(4):466–476. https://doi.org/10.1176/ajp.153.4.466
Kim DS, Szczypka MS, Palmiter RD (2000a) Dopamine-deficient mice are hypersensitive to dopamine receptor agonists. J Neurosci 20(12):4405–4413. https://doi.org/10.1523/JNEUROSCI.20-12-04405.2000
Kim HS, Park IS, Lim HK, Choi HS, Oh S, Park WK, Jang CG, Kim SH, Chang MJ (2000b) N-Methyl-D-aspartate receptor antagonists enhance the head-twitch response, a 5-hydroxytryptamine2 receptor-mediated behaviour, in reserpine-treated mice. J Pharm Pharmacol 52(6):717–722. https://doi.org/10.1211/0022357001774390
Kim M, Lee JG, Yang CH, Lee S (2016) Silica stationary phase-based on-line sample enrichment coupled with LC-MS/MS for the quantification of dopamine, serotonin and their metabolites in rat brain microdialysates. Anal Chim Acta 923:55–65. https://doi.org/10.1016/j.aca.2016.03.021
Kim M, Kim DH, Lee YS, Jang CG, Yang CH, Lee S (2017) Changes in dopamine, serotonin and their metabolites in brain microdialysates from rats following exposure to new psychoactive drugs. Forensic Toxicol 35:66–76. https://doi.org/10.1007/s11419-016-0335-8
Kim M, Yang CH, Lee YS, Jang CG, Oh S, Lee S (2019) Effects of aromatic ring-substituted phenethylamines on the release of dopamine and serotonin. Forensic Toxicol 37:104–112. https://doi.org/10.1007/s11419-018-0440-y
Koob GF, Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35(1):217–238. https://doi.org/10.1038/npp.2009.110
Korean Law Information Center (2019) Enforcement decree of the narcotics control act (Presidential Decree 30244). Korean. Korean Law Information Center Web. https://www.law.go.kr/LSW/nwRvsLsInfoR.do?lsiSeq=212321. Assessed 10 Dec 2019
Lee JG, Hur KH, Hwang SB, Lee S, Lee SY, Jang CG (2023) Designer drug, 25D-NBOMe, has reinforcing and rewarding effects through change of a dopaminergic neurochemical system. ACS Chem Neurosci 14(15):2658–2666. https://doi.org/10.1021/acschemneuro.3c00196
Lobo MK, Nestler EJ (2011) The striatal balancing act in drug addiction: distinct roles of direct and indirect pathway medium spiny neurons. Front Neuroanat 5:41. https://doi.org/10.3389/fnana.2011.00041
Lobo MK, Covington HE 3rd, Chaudhury D, Friedman AK, Sun H, Damez-Werno D, Dietz DM, Zaman S, Koo JW, Kennedy PJ, Mouzon E, Mogri M, Neve RL, Deisseroth K, Han MH, Nestler EJ (2010) Cell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward. Science 330(6002):385–390. https://doi.org/10.1126/science.1188472
Lobo MK, Zaman S, Damez-Werno DM, Koo JW, Bagot RC, DiNieri JA, Nugent A, Finkel E, Chaudhury D, Chandra R, Riberio E, Rabkin J, Mouzon E, Cachope R, Cheer JF, Han MH, Dietz DM, Self DW, Hurd YL, Vialou V, Nestler EJ (2013) ∆FosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J Neurosci 33(47):18381–18395. https://doi.org/10.1523/JNEUROSCI.1875-13.2013
McKinley JW, Shi Z, Kawikova I, Hur M, Bamford IJ, Sudarsana Devi SP, Vahedipour A, Darvas M, Bamford NS (2019) Dopamine deficiency reduces striatal cholinergic interneuron function in models of Parkinson’s disease. Neuron 103(6):1056–1072. https://doi.org/10.1016/j.neuron.2019.06.013
Meiser J, Weindl D, Hiller K (2013) Complexity of dopamine metabolism. Cell Commun Signal 11(1):34. https://doi.org/10.1186/1478-811X-11-34
Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA (2016) Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Front Neurosci 10:153. https://doi.org/10.3389/fnins.2016.00153
Miliano C, Marti M, Pintori N, Castelli MP, Tirri M, Arfè R, De Luca MA (2019) Neurochemical and behavioral profiling in male and female rats of the psychedelic agent 25I-NBOMe. Front Pharmacol 10:1406. https://doi.org/10.3389/fphar.2019.01406
Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H (1988) 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. Eur J Pharmacol 153(1):89–95. https://doi.org/10.1016/0014-2999(88)90591-2
Nairn AC, Svenningsson P, Nishi A, Fisone G, Girault JA, Greengard P (2004) The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 47:14–23. https://doi.org/10.1016/j.neuropharm.2004.05.010
Nazarian A, Russo SJ, Festa ED, Kraish M, Quinones-Jenab V (2004) The role of D1 and D2 receptors in the cocaine conditioned place preference of male and female rats. Brain Res Bull 63(4):295–299. https://doi.org/10.1016/j.brainresbull.2004.03.004
Nichols DE (2016) Psychedelics Pharmacol Rev 68(2):264–355. https://doi.org/10.1124/pr.115.011478
Nocjar C, Alex KD, Sonneborn A, Abbas AI, Roth BL, Pehek EA (2015) Serotonin-2 C and – 2a receptor co-expression on cells in the rat medial prefrontal cortex. Neuroscience 297:22–37. https://doi.org/10.1016/j.neuroscience.2015.03.050
Passie T, Benzenhöfer U (2018) MDA, MDMA, and other mescaline-like substances in the US military’s search for a truth drug (1940s to 1960s). Drug Test Anal 10(1):72–80. https://doi.org/10.1002/dta.2292
Pessia M, Jiang ZG, North RA, Johnson SW (1994) Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res 654(2):324–330. https://doi.org/10.1016/0006-8993(94)90495-2
Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM (2003) Subsecond dopamine release promotes cocaine seeking. Nature 422(6932):614–618. https://doi.org/10.1038/nature01476
Pruitt DL, Bolanos CA, McDougall SA (1995) Effects of dopamine D1 and D2 receptor antagonists on cocaine-induced place preference conditioning in preweanling rats. Eur J Pharmacol 283(1–3):125–131. https://doi.org/10.1016/0014-2999(95)00309-9
Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2 C drugs). Neuropharmacology 99:546–553. https://doi.org/10.1016/j.neuropharm.2015.08.034
Ru Q, Xiong Q, Tian X, Xu C, Li C, Chen L, Wu Y (2022) Candidate chinese herbal medicine alleviates methamphetamine addiction via regulating dopaminergic and serotonergic pathways. Front Mol Neurosci 15:874080. https://doi.org/10.3389/fnmol.2022.874080
Santana N, Artigas F (2017) Expression of serotonin2C receptors in pyramidal and GABAergic neurons of rat prefrontal cortex: a comparison with striatum. Cereb Cortex 27(6):3125–3139. https://doi.org/10.1093/cercor/bhw148
Self DW (2010) Dopamine receptor subtypes in reward and relapse. In: Neve K (ed) The dopamine receptors. Humana, New York, pp 479–524. https://doi.org/10.1007/978-1-60327-333-6_17
Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, Kim SK, Kim SE, Lee YS, Kim HC, Lee SY, Jang CG (2019) A novel designer drug, 25 N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull 152:19–26. https://doi.org/10.1016/j.brainresbull.2019.07.002
Soares-Cunha C, de Vasconcelos NAP, Coimbra B, Domingues AV, Silva JM, Loureiro-Campos E, Gaspar R, Sotiropoulos I, Sousa N, Rodrigues AJ (2020) Nucleus accumbens medium spiny neurons subtypes signal both reward and aversion. Mol Psychiatry 25(12):3241–3255. https://doi.org/10.1038/s41380-019-0484-3
Spanagel R (2017) Animal models of addiction. Dialogues Clin Neurosci 19(3):247–258. https://doi.org/10.31887/DCNS.2017.19.3/rspanagel
Suzuki J, Dekker MA, Valenti ES, Arbelo Cruz FA, Correa AM, Poklis JL, Poklis A (2015) Toxicities associated with NBOMe ingestion-a novel class of potent hallucinogens: a review of the literature. Psychosomatics 56(2):129–139. https://doi.org/10.1016/j.psym.2014.11.002
Swedish Code of Statutes (2018) Ordinance amending the ordinance (1992:1554) on the control of narcotics, SFS2018:2057. Swedish. Sveriges Riksdag Web. https://svenskforfattningssamling.se/sites/default/files/sfs/2018-12/SFS2018-2057.pdf. Assessed 20 Dec 2018
United States Code (2022) Controlled Substance Analogue, 21 U.S.C § 802(32)(A). UNITED STATES CODE Web. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802&num=0&edition=prelim
UNODC (2022) World Drug Report 2022. Booklet 4. United Nations publication, pp 87–103. United Nations Office on Drugs and Crime Web. https://www.unodc.org/res/wdr2022/MS/WDR22_Booklet_4.pdf
UK Statutory Instruments (2014) The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, 2014 No. 1106. UK Legislation Web. https://www.legislation.gov.uk/ukdsi/2014/9780111110904. Assessed 28 April 2014
Vickers SP, Easton N, Malcolm CS, Allen NH, Porter RH, Bickerdike MJ, Kennett GA (2001) Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2 C) receptor agonists. Pharmacol Biochem Behav 69(3–4):643–652. https://doi.org/10.1016/s0091-3057(01)00552-4
Volkow ND, Fowler JS, Wang GJ (2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 13(5–6):355–366. https://doi.org/10.1097/00008877-200209000-00008
Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9(6):557–569. https://doi.org/10.1038/sj.mp.4001507
Volkow ND, Wise RA, Baler R (2017) The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci 18(12):741–752. https://doi.org/10.1038/nrn.2017.130
Wojtas A, Herian M, Maćkowiak M, Solarz A, Wawrzczak-Bargiela A, Bysiek A, Noworyta K, Gołembiowska K (2023) Hallucinogenic activity, neurotransmitters release, anxiolytic and neurotoxic effects in Rat’s brain following repeated administration of novel psychoactive compound 25B-NBOMe. Neuropharmacology 240:109713. https://doi.org/10.1016/j.neuropharm.2023.109713
Wood DM, Sedefov R, Cunningham A, Dargan PI (2015) Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol (Phila) 53(2):85–92. https://doi.org/10.3109/15563650.2015.1004179
Zachariou V, Benoit-Marand M, Allen PB, Ingrassia P, Fienberg AA, Gonon F, Greengard P, Picciotto MR (2002) Reduction of cocaine place preference in mice lacking the protein phosphatase 1 inhibitors DARPP 32 or inhibitor 1. Biol Psychiatry 51(8):612–620. https://doi.org/10.1016/s0006-3223(01)01318-x
Zawilska JB, Kacela M, Adamowicz P (2020) NBOMes-Highly potent and toxic alternatives of LSD. Front Neurosci 14:78. https://doi.org/10.3389/fnins.2020.00078
Acknowledgements
This work was supported by the National Research Foundation of Korea and funded by the Ministry of Education (2022R1A6A1A03054419) and the Korea Food and Drug Administration (22214MFDS251).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no biomedical financial interests or potential conflicts of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kim, YJ., Kook, WA., Ma, SX. et al. The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents. Arch. Pharm. Res. 47, 360–376 (2024). https://doi.org/10.1007/s12272-024-01491-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-024-01491-4